Lisdexamfetamine Dimesylate Capsule
Product Images NDC 72162-2452

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Lisdexamfetamine Dimesylate (NDC 72162-2452). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl721622452)

Lisdexamfetamine Dimesylate Capsules 20 mg label showing the NDC 72162-2452-1. The label includes storage instructions, a warning to keep out of reach of children, and mentions that the product is relabeled by Bryant Ranch Prepack, Inc., and manufactured by Purdue Pharma L.P. The package contains 100 capsules and is prescription only.*

FDA Label Image

Chemical Structure (Lisdexcaps 01)

Chemical structure of lisdexamfetamine dimesylate, showing the molecular arrangement of the active ingredient including the amine groups and methanesulfonate components.*

FDA Label Image

Figure 1 (Lisdexcaps 02)

A scatter plot with horizontal error bars illustrating the fold change and 90% confidence intervals of pharmacokinetic parameters Cmax and AUC in various special populations, including gender, age groups (65-74 years, 75+ years), and renal impairment stages (mild, moderate, severe, end stage renal disease). The x-axis represents change relative to reference with values from 0.0 to 2.5.*

FDA Label Image

Figure 2 (Lisdexcaps 03)

A forest plot chart showing the fold change and 90% confidence interval for pharmacokinetic parameters Cmax and AUC caused by Guanfacine, Venlafaxine, and Omeprazole. The x-axis represents the fold change relative to reference from 0.0 to 2.0, with a vertical line at 1.0 indicating no change. Points with error bars illustrate the changes for each drug and parameter.*

FDA Label Image

Figure 3 (Lisdexcaps 04)

A forest plot chart depicting the pharmacokinetic (PK) interactions of various drugs, showing fold change and 90% confidence intervals for Cmax and AUC values relative to reference. Drugs include Guanfacine, Venlafaxine, caffeine (CYP1A2 substrate), dextromethorphan (CYP2D6 substrate), omeprazole (CYP2C19 substrate), and midazolam (CYP3A substrate). The x-axis represents the change relative to reference from 0.0 to 2.0.*

FDA Label Image

Figure 4 (Lisdexcaps 05)

A line graph comparing LS Mean SKAMP Deportment Scores over time post-dose between Lisdexamfetamine and placebo. The x-axis represents time in hours post-dose (from 0 to 13), and the y-axis shows SKAMP scores ranging from 0 to 2. The graph has two lines: a solid line for Lisdexamfetamine showing lower scores over time, and a dashed line for placebo showing higher scores. Error bars indicate variability at each time point.*

FDA Label Image

Figure 5 (Lisdexcaps 06)

A line graph comparing the proportion of subjects with relapse or treatment failure over time (days after randomization) between lisdexamfetamine and placebo groups. The graph shows a lower relapse rate over time for lisdexamfetamine compared to placebo.*

FDA Label Image

Figure 6 (Lisdexcaps 07)

A line graph comparing LS Mean (SE) PERMP Total Scores over time post-dose in hours for Lisdexamfetamine and placebo. The x-axis shows time post-dose (hours) from -0.5 to 14 hours, and the y-axis shows scores ranging from 250 to 330. The graph features two lines: a solid line for Lisdexamfetamine showing higher total scores over time, and a dashed line for placebo with lower scores. Error bars indicate variability at each time point.*

FDA Label Image

Figure 7 (Lisdexcaps 08)

A line graph comparing the proportion of subjects with relapse or treatment failure over time (days after randomization) between Lisdexamfetamine and placebo groups. The graph shows time on the x-axis up to 40 days, and the proportion of subjects on the y-axis up to 100%. The placebo group line increases steadily, while the Lisdexamfetamine group line remains low and stable.*

FDA Label Image

Figure 8 (Lisdexcaps 09)

Kaplan-Meier survival plot showing the proportion of subjects with release over time (days after randomization) comparing Lisdexamfetamine and Placebo groups. The x-axis represents time in days, and the y-axis shows the proportion of subjects with release in percentage. The chart includes numbers of subjects at risk for both treatment arms at specified time points.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.